Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 06 Mar 2023
USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...
Read Full NewsTrial data showed that treatment with lamotrigine reduced myotonia severity in adults with genetically confirmed non-dystrophic myotonias, with sustained benefit and an acceptable safety profile.
The neurologist in the Department of Neurology at Saratoga Hospital Medical Group shared what excites her most about the future of neurology, specifically for movement disorders, in 2026.
COPD Drug Withdrawal Tied to Early Exacerbation, With Alexander Mathioudakis, MD, PhD
FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD
FDA Approves Labeling Update for iDose TR for Open-Angle Glaucoma and Ocular Hypertension
Apecotrep Delivers 40% Proteinuria Reduction in Phase 2 FSGS Trial
FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates
1.
improvements in the treatment of prostate cancer resistant to chemotherapy.
2.
An inhibitor of JAK1 exhibits "remarkable" activity in T-cell lymphoma.
3.
BlurryScope: A compact, AI-powered microscope for rapid, cost-effective cancer scoring
4.
Millions of men could benefit from faster scan to diagnose prostate cancer
5.
Immunotherapy Is As Safe As Other Cancer Treatments During Pregnancy.
1.
Breast Cancer Secrets: AI-Powered Precision Medicine
2.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
3.
What Is Gastrinoma? Understanding This Rare Tumor and Its Treatment Options
4.
The Miracle of Tenecteplase: How This Drug Is Saving Lives
5.
ctDNA in Aggressive B-Cell Lymphoma: Redefining MRD and Prognostic Monitoring
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge